Welcome to our dedicated page for Aditxt news (Ticker: ADTX), a resource for investors and traders seeking the latest updates and insights on Aditxt stock.
Aditxt Inc (ADTX) is a pioneering biotechnology company developing innovative solutions to reprogram immune responses, with applications in organ transplantation and autoimmune disorders. This dedicated news hub provides investors and researchers with timely updates on clinical advancements, regulatory milestones, and strategic partnerships.
Access authoritative reporting on ADTX's flagship programs including Adimune for transplant tolerance and AditxtScore diagnostic platforms. Track developments in Apoptotic DNA Immunotherapy (ADi) and other novel approaches to immune modulation. The curated news feed covers earnings reports, research collaborations, and product pipeline updates while adhering to financial disclosure standards.
Bookmark this page for consolidated access to press releases, clinical trial data disclosures, and expert analyses of ADTX's position in the competitive immunotherapy landscape. Stay informed about technological breakthroughs through verified updates from primary sources.
Aditxt, Inc. (NASDAQ: ADTX) announced a private placement offering under Nasdaq rules, pricing the sale of convertible preferred stock, preferred stock, and warrants to purchase common stock, expected to raise approximately $4.2 million. The offering is set to close around May 6, 2024, with proceeds intended for merging expenses and general corporate purposes.
Aditxt, Inc. announced a $4.2 million private placement priced under Nasdaq rules, including the sale of convertible preferred stock, preferred stock, and warrants to purchase common stock. The offering is expected to close on or about May 6, 2024, with gross proceeds to be used for merger obligations and general purposes.
FAQ
What is the current stock price of Aditxt (ADTX)?
What is the market cap of Aditxt (ADTX)?
